Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
American chemical industry news
(page 8)
5 March 2026
RWE Adds 2 GW to U.S. Energy Capacity
RWE completed 15 projects in 2025, adding solar, wind, and battery storage across seven U.S. states, creating 3,500 jobs and investing over $500 million in local communities.
5 March 2026
Neste Releases 2025 Green Finance Report
Neste allocated EUR 610M to Rotterdam's refinery expansion, boosting renewables capacity. EUR 510M remains unallocated. The 2025 report highlights strong investor support for green projects.
5 March 2026
Neste Leadership and Organizational Changes
Neste appoints new leadership for Renewable Products, adds a North America unit, and integrates commercial, refining, and feedstock sourcing into its leadership team.
4 March 2026
Topsoe's 2025 Financial Results Meet Expectations in Tough Market
Revenue reached DKK 8,197 million. EBIT margin at 8.9%. SAF projects in China. New CEO from March 2026. 2026 outlook: revenue DKK 7,600-8,400 million, EBIT margin 0.0-5.0%.
4 March 2026
Symrise Reports 2025 Organic Sales Growth and Profitability Boost
Achieved 2.8% organic growth, 21.9% EBITDA margin, and launched share buyback. Focused on efficiency, innovation, and strategic transformation for long-term value.
3 March 2026
GSK Finalizes RAPT Therapeutics Acquisition
GSK acquires ozureprubart, a potential long-acting anti-IgE therapy for food allergies, with phase IIb data expected in 2027. The deal is valued at $2.2 billion.
How does the American chemical industry perform?
Find out with
chemXplore Alpha
Learn more
3 March 2026
Johnson & Johnson's Nipocalimab Gets FDA Fast Track for Lupus Treatment
Nipocalimab, an investigational therapy, aims to address unmet needs in lupus by reducing harmful IgG while preserving immune function, following positive Phase 2b results.
2 March 2026
PPG, IPG Photonics, Whirlpool Advance Laser-Based Powder Curing
Laser curing offers faster, energy-efficient powder coating, reducing costs and environmental impact. Pilot trials underway to enhance productivity and sustainability.
2 March 2026
Takeda's Rusfertide Receives FDA Priority Review
Rusfertide shows promise in controlling hematocrit and reducing symptoms in polycythemia vera, with FDA review based on positive Phase 3 and long-term study data.
2 March 2026
WuXi Biologics in S&P Global Sustainability Yearbook for Fourth Year
Recognized for top sustainability performance, achieving a Top 1% S&P Global CSA Score, and earning multiple ESG accolades across various indices and initiatives.
28 February 2026
Merck's KEYTRUDA and WELIREG Combo Reduces RCC Recurrence Risk by 28%
Phase 3 trial shows KEYTRUDA and WELIREG improve disease-free survival in RCC. FDA accepts priority review for adjuvant treatment. Safety profile consistent with previous studies.
28 February 2026
Merck and Eisai: WELIREG and LENVIMA Reduce Disease Progression Risk by 30% in Advanced RCC Trial
Phase 3 trial shows WELIREG plus LENVIMA improves progression-free survival in advanced RCC, with FDA reviewing new drug applications.
27 February 2026
FDA Approves Novo Nordisk's Sogroya for New Pediatric Uses
Sogroya, a once-weekly growth hormone, is now approved for children with ISS, SGA, or NS, offering an alternative to daily injections and expanding treatment options.
27 February 2026
Merck's KEYTRUDA and Padcev Cut Event-Free Survival Risk by 47% and Mortality by 35% in Cisplatin-Eligible Bladder Cancer Patients
KEYTRUDA plus Padcev improves survival and reduces recurrence in muscle-invasive bladder cancer, showing potential as a new standard for cisplatin-eligible patients.
27 February 2026
Merck's KEYTRUDA Plus Paclitaxel Boosts Survival in Platinum-Resistant Ovarian Cancer
KEYTRUDA plus paclitaxel improves overall survival in platinum-resistant ovarian cancer, regardless of PD-L1 status, as shown in the KEYNOTE-B96 trial.
27 February 2026
Lilly's Olumiant Gains CHMP Nod for Adolescent Alopecia Areata in EU
CHMP backs Olumiant for severe alopecia areata in adolescents, based on Phase 3 study showing 42% achieved 80% scalp hair coverage at 36 weeks. Awaiting European Commission decision.
27 February 2026
CABB Group Sells Jayhawk Fine Chemicals to Anupam Rasayan
CABB shifts focus to Pharma and Life Science, selling Jayhawk for $150M. Anupam Rasayan aims to expand its US presence and performance materials business.
27 February 2026
Ercros Reports EUR 8M EBITDA, EUR 54M Loss
Weak demand, high energy costs, and competition impact results. Cost reduction plan on track. Financial debt reduced. Takeover bid rejected. Demand recovery expected in late 2026.
26 February 2026
GSK's Linerixibat Gets Priority Review in China for PBC-Related Itch
Linerixibat shows significant improvement in cholestatic pruritus in PBC patients, based on GLISTEN phase III trial data. Regulatory reviews ongoing in US, EU, UK, and Canada.
26 February 2026
thyssenkrupp Automotive Body Solutions Joins IPAI for Smart Manufacturing Innovation
The company joins IPAI to integrate AI in manufacturing, enhancing robotics and expanding globally, with a focus on intelligent production and quality monitoring.
26 February 2026
MOL Accuses JANAF of Legal Violations Over Russian Oil Transit
MOL demands JANAF allow unsanctioned Russian oil via sea, citing EU/US rules. Non-compliance may lead to legal action and claims for damages.
26 February 2026
PureCycle Technologies Q4 2025 Results and Update
Record production, revenue growth, expansion in Thailand and Belgium, and leadership changes. Gen-2 design shows cost efficiency. Financials stable with ongoing projects and debt management.
26 February 2026
TotalEnergies to Export 2 Mtpa LNG from Alaska Project for 20 Years
The Alaska LNG project, with a 20 Mtpa capacity, aims to supply Asia, enhancing energy security and transpacific ties. It has strong U.S. support and offers logistical advantages.
26 February 2026
FDA Approves Boehringer Ingelheim's HERNEXEOS for HER2-Mutant NSCLC
HERNEXEOS gains FDA approval for HER2-mutant NSCLC, showing a 76% response rate in trials. Further confirmation required for continued approval.
26 February 2026
BASF Introduces Biomass Balance Autofroth Foam for North American Market
BMB Autofroth foam cuts carbon emissions by 18-20%, offers a drop-in solution for sustainability without process changes, and suits various applications.
26 February 2026
Lilly's Orforglipron Outperforms Semaglutide in Diabetes Trial
Orforglipron 36 mg reduced A1C by 2.2% and weight by 9.2%, surpassing semaglutide in a 52-week trial with 1,698 participants. Results published in The Lancet.
26 February 2026
Veolia 2025 Results Overview
Strong 2025 results with growth in international markets, early ROCE target achievement, key acquisitions, increased dividend, and positive 2026 outlook.
26 February 2026
Covestro Meets 2025 Guidance Amid Challenges
Sales and EBITDA fell in 2025. Strategic moves and partnerships aim to boost growth. 2026 outlook: stable EBITDA, improved cash flow, and reduced emissions.
26 February 2026
Technip Energies 2025 Financial Results
Strong 2025 results with revenue and EBITDA growth, dividend increase, share buyback, and strategic acquisition. Positive outlook for 2026 with robust backlog and sustainability focus.
26 February 2026
2025 Results: Arkema Performance Summary
Strong cash flow and EBITDA, sales growth in key markets, successful capacity expansions, and sustainability progress. Dividend stable; 2026 targets slight EBITDA growth amid weak demand.
← Previous
Next →
